Helius Medical Technologies, Inc. Announces Participation of Dr. Prue Plummer
Fourth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate impact of subjects’ adherence to PoNS® therapy for gait improvement in Multiple Sclerosis
NEWTOWN, Pa., Nov. 09, 2022 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT)
Helius Medical Technologies, Inc. has recently announced the addition of Dr. Prue Plummer as a participant in their multi-center, company-sponsored trial. This open-label observational interventional trial aims to evaluate the impact of subjects’ adherence to PoNS® therapy for gait improvement in Multiple Sclerosis patients.
The addition of Dr. Prue Plummer and the fourth Center of Excellence marks a significant milestone in the ongoing effort to improve neurological wellness. By expanding the reach of this trial, Helius Medical Technologies is taking a proactive approach to address the needs of patients with Multiple Sclerosis who struggle with gait issues.
The PoNS® therapy has shown promising results in previous studies, and with the inclusion of Dr. Prue Plummer, a renowned expert in the field of neurology, the trial is expected to provide valuable insights into the effectiveness of this innovative treatment.
Multiple Sclerosis is a complex neurological condition that can significantly impact a person’s quality of life. Gait issues, in particular, can make everyday tasks challenging and affect overall mobility. By focusing on gait improvement, Helius Medical Technologies aims to enhance the lives of patients living with Multiple Sclerosis.
Dr. Prue Plummer’s expertise and dedication to neurological wellness make her a valuable addition to this trial. Her insights and contributions are expected to further advance our understanding of the benefits of PoNS® therapy for patients with Multiple Sclerosis.
Overall, the participation of Dr. Prue Plummer and the establishment of the fourth Center of Excellence demonstrate Helius Medical Technologies’ commitment to driving innovation in neurotechnology and improving patient outcomes.
How this will affect me:
As a patient with Multiple Sclerosis, the participation of Dr. Prue Plummer and the development of this trial could potentially offer new treatment options for improving gait issues. By evaluating the impact of PoNS® therapy on gait improvement, this trial may provide valuable insights into managing the symptoms of Multiple Sclerosis and enhancing mobility.
How this will affect the world:
The addition of Dr. Prue Plummer and the expansion of the trial to include a fourth Center of Excellence signifies a significant advancement in the field of neurotechnology. The findings from this trial could have far-reaching implications for patients with neurological conditions beyond Multiple Sclerosis, paving the way for innovative treatments and improved outcomes worldwide.
Conclusion:
The participation of Dr. Prue Plummer in Helius Medical Technologies’ trial marks a pivotal moment in the quest to improve neurological wellness. By focusing on gait improvement in Multiple Sclerosis patients, this trial has the potential to revolutionize treatment options and enhance the lives of individuals with neurological conditions. The commitment to innovation and collaboration demonstrated by Helius Medical Technologies sets a new standard for advancing neurotechnology and improving patient outcomes globally.
